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Hospital Utrecht and Kennemer Gas-
thuis Haarlem in the Netherlands 
and University Hospital Gasthuis-
berg Leuven in Belgium). All low-
dose chest CT scans were performed 
by using 16-detector helical CT scan-
ners Sensation-16, Siemens Medical 
Systems or, at the screening site in 
Utrecht, Mx8000 IDT or Brilliance 
16P, Philips Medical Systems). Scan-
ning of the entire chest was per-
formed in a caudo-cranial direction, 
without the use of contrast agents. 
Depending on body weight (< 50 kg, 
50-80 kg, and > 80 kg), the kVp set-
tings were 80-90, 120 and 140 kVp 
respectively. This corresponds to an 
effective radiation dose < 1.6 mSv. 
Data sets of the lung were recon-
structed at 1.0-mm slice thickness, 
with 0.7-mm reconstruction incre-
ment. Scans were performed in in-
spiration after appropriate instruc-
tion of the participants, to minimize 
breathing artefacts.
Data acquisition and scanning 
conditions were standard across 
screening centres and equal for 
baseline and repeat screening (9). 
Volumetric measurements and 
image reading
Digital workstations (Leonardo, 
Siemens Medical Solutions) were 
used for nodule volumetric analysis. 
This system detected automatically 
whether a nodule, marked by a 
 radiologist, was new or had been 
present previously. After a nodule 
was marked, a program for semi- 
automated volume measurements 
(LungCare, version Somaris/5 VB 
10A-W, Siemens Medical Solutions) 
automatically defined the volume of 
interest around the nodule. An 
 observer could manually modify the 
segmentation by increasing or de-
creasing the volume, if necessary (9). 
Data generated by the LungCare 
software were uploaded into the 
NELSON Management System, 
which automatically detected wheth-
er a nodule was new or present on 
previous scans. The percentage vol-
ume change and VDT of previously 
detected nodules were calculated 
results will indicate whether a volu-
metry- and VDT based CT protocol is 
more efficient in terms of detection 
rate, morbidity, mortality, recall rate, 




The NELSON multi-centre trial 
was approved by the Dutch Minister 
of Health and the ethics board at 
each participating centre. All partici-
pants provided written informed 
consent. Participants were recruited 
based on a questionnaire about 
health, smoking, cancer history, and 
other lifestyle and health factors. In-
cluded were current or former heavy 
smokers, with a history of > 15 ciga-
rettes daily for > 25 years or > 10 ciga-
rettes daily for > 30 years and be-
tween 50-75 years of age. Exclusion 
criteria were a moderate or bad self 
reported health, inability to climb 
two flights of stairs, body weight 
≥ 140 kg, lung cancer less than 
5 years ago or still under treatment, 
current or past renal cancer, mela-
noma or breast cancer, and chest CT 
less than 1 year ago (8). In total, 
15,822 subjects were included. 7,557 
were categorized in the screen 
group, receiving low-dose chest CTs. 
Participants in the control group re-
ceived no screening.
Participants in the screen group 
underwent CT, and depending on 
the screening round, pulmonary 
function testing and blood sampling 
on the same day. After each CT ex-
amination, participants completed a 
quality of life questionnaire.
Data acquisition
The participants randomized to 
the screen group were invited to one 
of the four screening sites (Universi-
ty Hospital Groningen, University 
Lung cancer is a major health 
problem with no improvement in 
survival over the last decades. At 
time of diagnosis, lung cancer is of-
ten already in advanced stage, with 
5-year survival of no more than 
15% (1). Currently, several lung can-
cer screening trials investigating 
whether early detection of lung can-
cer in high-risk individuals will even-
tually reduce lung cancer mortality 
are ongoing (2-7). To date, the Na-
tional Lung Screening Trial (NLST) is 
the only randomized controlled trial 
in which a significant lung cancer 
mortality reduction was found (2).
The Dutch-Belgian lung cancer 
screening trial (Dutch acronym: NEL-
SON study) was launched in Sep-
tember 2003. The NELSON study is 
an ongoing multicentre randomized 
controlled multi-detector low-dose 
computed tomography lung cancer 
screening trial. The primary object is 
to investigate whether chest CT 
screening in year 1, 2, 4 and 6.5 will 
decrease lung cancer mortality by at 
least 25% in high-risk (ex-)smokers 
between 50 and 75 years of age com-
pared to a control group receiving no 
screening. Secondary end points of 
the study include estimation of the 
cost-effectiveness of the screening 
programme, assessment of the opti-
mal screening interval (1, 2 or 2.5 
years), and assessment of the impact 
on quality of life. In addition, multi-
ple side studies are ongoing.
One of the major challenges in 
lung cancer screening is the high 
false-positive rate, causing patient 
anxiety, cost and morbidity associ-
ated with unnecessary diagnostic 
procedures for benign nodules. The 
NELSON trial is the first large lung 
cancer screening trial in which the 
nodule management protocol is 
based on nodule volume, instead of 
nodule diameter, and nodule growth, 
in terms of volume doubling time 
(VDT) of existing nodules. The final 
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Fig. 1. — Growing malignant lesion in a 65-year-old man. Axial computed tomography (CT) scan (A) shows a nodule (arrow) with 
a volume of 259 mm3 in the left lower lobe. Three months later (B), the nodule volume increased to 270 mm3 (volume-doubling time 
[VDT] = 1468 days). One year after baseline CT (C), the nodule volume was 425 mm3 (VDT = 528 days). 28 months after baseline CT 
(D), the nodule volume was 1132 mm3. The VDT at that time was 289 days. Lobectomy revealed a stage IA adenocarcinoma. 
M.a.b. = months after baseline.
the third round examination 2 years 
after the second round (9).
The protocols of the third and 
fourth-round examinations were 
comparable to the protocol of the 
second-round, except for the fact 
that the fourth-round examination 
was planned 2.5 years after the third-
round examination. The screening 
program ended after a positive or 
negative fourth round result, or, in 
case of an indeterminate fourth-
round result, after a positive or nega-
tive follow-up CT (Fig. 2).
Test positives were referred to a 
pulmonologist for workup. Workup, 
staging, and treatment were stan-
dardized to (inter-) national guide-
lines (9, 11). Nodules were classified 
as benign or malignant based on his-
tological examination. Also, nodules 
could be classified benign based on 
stable or decreasing size two years 
after first detection (12, 13). If lung 
cancer was diagnosed, the participant 
was treated and left the screening tri-




The results of the first and second 
screening round were published in 
Indeterminate nodules underwent 
a 3-month follow-up CT to assess for 
growth. Growth was defined as vol-
ume increase of at least 25%. For 
growing nodules, the final result was 
based on their VDT. If a growing lesion 
had a VDT < 400 days, the final result 
was positive. Otherwise the baseline 
result was negative and the partici-
pant was invited for the regular sec-
ond-round examination in year 2. 
At second-round screening, there 
were two possibilities: either a nod-
ule was new, and the result was 
based on nodule size, or a nodule 
was pre-existing. New indeterminate 
nodules underwent a 6-weeks fol-
low-up CT. For pre-existing nodules, 
the second round result was based 
on their VDT immediately. If both 
new and existing nodules were pres-
ent, the nodule with the largest vol-
ume or fastest growth determined 
the result. Again, a VDT < 400 days 
resulted in a positive screen result. A 
nodule with VDT > 600 was classified 
as negative. A VDT of 400-600 days 
comprised an indeterminate result; 
then a follow-up CT was made 1 year 
later. Then, if the VDT was less than 
400 days, the final result was posi-
tive (Fig. 1), otherwise negative. All 
participants with a negative second-
round result were invited to undergo 
automatically by the system. For 
each evaluable nodule, the surface 
characteristics, location, distance to 
the pleura, and aspect of the nodule 
(i.e. solid, nonsolid or partial solid) 
were entered in the NELSON Man-
agement System by a radiologist.
All CT images were independently 
read by first and second readers 
(double reading) as part of the NEL-
SON protocol (9). The first reading 
was performed by a reader with ex-
perience in reading chest CTs vary-
ing from none to more than 20 years; 
the second reading was performed 
by two readers, each with 6 years of 
experience. The second readers 
were unaware of the conclusions of 
the first readers. In case of discrep-
ancy, the final decision was made by 
a third reader (10).
Screening strategy
At baseline, a test was considered 
positive if any non-calcified nodule 
was larger than 500 mm3 (> 9.8-mm 
diameter). The result was indetermi-
nate if the volume of the largest solid 
nodule or the solid component of a 
partially-solid nodule was 50-500 mm3 
(4.6-9.8-mm diameter). In case of 
smaller nodules, the screening was 
negative (9).
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reconstruction settings was found. It 
was shown that volume measure-
ment of pulmonary nodules obtained 
at 1 mm section thickness combined 
with a soft kernel was most repeat-
able. Therefore it was concluded that 
in case of serial CT studies, consis-
tent reconstruction parameters are 
essential. Furthermore, compared to 
single reading, no statistically signif-
icant benefit for consensus double 
reading at baseline screening for 
lung cancer with the use of a nodule 
management strategy based solely 
on semi-automated volumetry was 
found (18). Therefore, in the fourth 
screening round image reading was 
performed by only one reader. 
At last, the performance of com-
puter aided detection (CAD) was 
compared to double reading. The 
false-positive rate was 3.7 per CT for 
CAD and 0.5 per CT for readers. Ex-
cluding small nodules (< 50 mm3), 
the false-positive rate for CAD de-
creased to 1.9. The sensitivity of nod-
ule detection by readers for nodules 
with need of further evaluation could 
have increased by 18.6% (from 78.1% 
to 96.7%) if CAD had also been used. 
However, only one lung cancer 
missed by readers was detected by 
CAD (19).
Three studies focussed on the 
work-up of pulmonary nodules. In 
the first (20), it was shown that con-
ventional white-light bronchoscopy 
should not be routinely recommend-
ed for patients with a positive test 
result in a lung cancer screening tri-
al. The overall sensitivity was 13.5% 
and the negative predictive value 
was 47.6%. In the second study (21), 
the role of a preoperative positron 
emission tomography after a conclu-
sive or inconclusive nonsurgical 
workup was evaluated. It was con-
cluded that a preoperative PET scan 
in participants with an inconclusive 
nonsurgical workup is not recom-
mended because of the very low 
negative predictive value. The third 
study (22) investigated the complica-
tion rate in participants of the screen 
arm of the NELSON lung cancer 
screening trial who underwent surgi-
cal resection. They found that mor-
tality rates after surgical procedures 
are lower in the NELSON lung cancer 
screening trial than those in the non-
screening series. The rate of compli-
cations is within the same range as 
in the non-screening series.
A number of studies focussed on 
the characteristics of lung nodules 
associated with cancer risk. In solid 
nodules larger than 50mm3, especial-
ly size, and to a lesser extent irregu-
lar shape and margin, were found to 
increase the likelihood of malignan-
cy (13). Although baseline lung 
dose CT screening. The control 
group received 3 annual rounds of 
chest X-ray screening (2).
In the NLST screening rounds, the 
rate of positive tests, defined as 
greatest nodule diameter of 4 mm or 
larger, was 24%. No less than 96.4% 
comprised false positive results. Vol-
ume-based nodule management has 
been suggested to be more accurate 
than diameter measurements (14, 
15), potentially leading to lower 
false-positive rates. Therefore, the 
NELSON trial was the first lung can-
cer screening trial which based 
screening interpretation on nodule 
volumetry and growth in terms of 
volume doubling time instead of di-
ameters. This strategy yielded a rath-
er low rate of positive screening tests 
(2.6% in the baseline screening; 1.8% 
in the second-round screening), 
while the number of missed lung 
cancers was low.
Additional results of the NELSON 
study
Valuable knowledge about in-
terobserver variability and the opti-
mal image reading protocol of semi-
automated volume measurements 
was obtained in the NELSON trial. 
Gietema et al. found that interob-
server correlation was very high 
(r = 0.99) in small-to-intermediate 
size (15-500 mm3) lung nodules (10). 
It was also found that variability on 
volume measurements is related to 
nodule size, morphology and loca-
tion (16). In a further study (17), a dif-
ference in repeatability among three 
the New England Journal of Medi-
cine in 2009 (7). In the baseline 
round, 1.6% of the subjects in the 
screen group had a nodule with vol-
ume > 500mm3. 19.2% had at least 
one indeterminate nodule, for which 
a three-month follow-up CT was per-
formed. In this follow-up CT, growth 
was demonstrated in only 5.3% of 
participants with indeterminate nod-
ules. In total, 196/7,557 participants 
tested positive (2.6%). In 70/196 
 participants, malignancy was con-
firmed; the lung cancer detection 
rate was 0.9%. Sensitivity of the 
baseline round screening was 94.6%, 
the negative predictive value was 
99.7%. Only three interval cancers 
were detected between the first and 
second screening round.
In the second screening round, a 
total of 7,289 participants underwent 
screening. The screen result was 
negative in 92.2% of the participants, 
indeterminate in 6.6% and positive in 
1.2%. After follow-up examinations 
for indeterminate tested nodules, a 
total of 128/7,289 participants (1.8%) 
tested positive. Malignancy was con-
firmed in 54/118 (45.8%) participants 
referred for work-up. The lung can-
cer detection rate was 0.8%. Sensi-
tivity of the second round screening 
was 96.4%, the negative predictive 
value was 99.9%. 
NELSON vs NLST
Recently, the American National 
Lung Cancer Screening trial pub-
lished a 20% lung cancer mortality 
reduction in their study group which 
received 3 annual rounds of low-
Fig. 2. — Screening programme
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16. Wang Y., van Klaveren R.J., van der 
Zaag-Loonen H.J., de Bock G.H., 
 Gietema H.A., Xu D.M., et al.: Effect of 
 nodule CT density was not predictive 
of malignancy, an increase in CT 
density on follow-up CTs in inter-
mediate-sized nodules suggested 
lung cancer (23).
Cancers in intermediate-sized (50-
500 mm3) fast-growing solid nod-
ules, diagnosed at 3-month or 1-year 
follow-up CT after baseline, were 
found to be non-spherical and purely 
intraparenchymal, without attach-
ment to the pleura, vessels or fis-
sures (24). Perifissural nodules, ac-
counting for about 20% of all lung 
nodules found in lung cancer screen-
ing, can show growth rates in the 
range of malignant nodules. Howev-
er, none of the perifissural nodules 
turned out to be malignant after 
5.5 years of follow-up. Therefore, 
recognition of these nodules can re-
duce unnecessary workup (25).
Conclusion
The first results of the NELSON 
study show the value of 3D-based 
lung nodule management for CT 
lung cancer screening, with very 
high negative predictive values 
found in the first and second screen-
ing round. Follow-up of the NELSON 
study population is ongoing and the 
mortality results are pending, but the 
unique methodological features of 
this randomized trial have already 
yielded important insights that com-
plement the information gained from 
NLST.
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